Probabilistic cost-effectiveness analysis of controlled ovarian stimulation with recombinant FSH plus recombinant LH vs. Human menopausal gonadotropin for women undergoing IVF by Mennini, F. S. et al.
RESEARCH Open Access
Probabilistic cost-effectiveness analysis of
controlled ovarian stimulation with
recombinant FSH plus recombinant LH vs.
human menopausal gonadotropin for
women undergoing IVF
F. S. Mennini1,2, A. Marcellusi1,2, R. Viti1, C. Bini1*, A. Carosso3, A. Revelli3,4 and C. Benedetto3
Abstract
Background: The association of recombinant FSH plus recombinant LH in 2:1 ratio may be used not only to induce
ovulation in anovulatory women with hypogonadotropic hypogonadism but also to achieve multiple follicular
developments in human IVF. The aim of this analysis was to estimate the cost-effectiveness of Controlled Ovarian
Stimulation (COS) with recombinant FSH (rFSH) plus recombinant LH (rLH) in comparison with highly purified
human menopausal gonadotropin (HP-hMG) in the woman undergoing in vitro fertilization (IVF) in Italy.
Methods: A probabilistic decision tree was developed to simulate patients undergoing IVF, either using r-FSH + r-LH or
HP-hMG to obtain COS. The model considers the National Health System (NHS) perspective and a time horizon equal to
two years. Simulations were reported considering the number of retrieved oocytes (5–9, 10–15 and > 15) and transition
probabilities were estimated through specific analyses carried out on the population of 848 women enrolled
in the real-life.
Results: The model estimated that patients undertaking therapeutic protocol with r-FSH + r-LH increase the general
success rate (+ 6.6% for pregnancy). The incremental cost-effectiveness ratio (ICER) per quality-adjusted life year (QALY)
of r-FSH + r-LH was below the willingness to pay set at €20,000 for all the considered scenarios.
Conclusions: The cost-utility analysis demonstrated that the r-FSH + r-LH is a cost-effective option for the Italian
National Health System (NHS).
Keywords: Real world data, Retrieved oocytes, Cost-utility, QALYs
Background
The twentieth century witnessed the discovery of pituitary
gonadotropins follicle-stimulating hormone (FSH) and
luteinising hormone (LH) that were made available as
medication after the extraction and purification from
the urine of menopausal women [1]. The combination
of urinary FSH (u-FSH) and human chorionic gonado-
tropin (u-hCG), a placental hormone displaying LH activity,
has been available for the last forty years under the
name of “human Menopausal Gonadotropin” (hMG)
About twenty-five years ago, genetic engineering devel-
oped recombinant FSH (r-FSH) and recombinant LH
(r-LH) by inserting the corresponding human DNA into
Chinese hamster cells and then extracting and purifying
the final molecules from their supernatant [2, 3]. Now-
adays a highly purified hMG (HP-hMG, Meropur, Ferring
Germany) has been introduced.
Urinary-derived and recombinant gonadotropins have
been widely used to treat women with infertility due
to chronic anovulation [4], or to provide a therapeutic
stimulation to spermatogenesis [5]. In most cases,
however, these are administered to obtain the so-called
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Controlled Ovarian Stimulation (COS), that is the multiple
follicular developments aimed at getting the number
of oocytes needed to perform in vitro fertilization
(IVF). Several studies, as well as systematic reviews, have
compared the effectiveness of urinary gonadotropins
(u-FSH or HP-hMG) vs. r-FSH for COS, showing the su-
periority of r-FSH over u-FSH [4, 6, 7] and a substantial
equivalence of r-FSH and HP-hMG [8–13]. Also, only
in few countries the combination of r-FSH + r-LH in a
2:1 ratio (Pergoveris, Merck, Germany) for the treat-
ment of patients with hypogonadotropic hypogonadism
[14], is also licensed for COS. Comparative studies vs.
hMG are rare and substantial do information are still
missing [15, 16]. To date, the largest study comparing
r-FSH + r-LH vs. HP-hMG in human IVF was con-
ducted retrospectively on real-life data from clinical
practice that were obtained in the IVF Unit of a University
Hospital and in a private IVF Clinic [17]. In this context
the r-FSH + r-LH association was demonstrated: (1) as
effective as HP-hMG when the retrieved oocytes were less
than 4, slightly (but not significantly); (2) superior when
the retrieved oocytes were 5–8 and(3) significantly more
effective in terms of pregnancy rate per embryo transfer
(PR/ET) when they were 9 or more [17]. Moreover, in the
same study, the advantage of using the r-FSH + r-LH ther-
apy was even more pronounced when only mature
oocytes were considered [17]. In support of the mentioned
results, a multivariate logistic regression model confirmed
that both the use of recombinant gonadotropins and the
number of retrieved oocytes were increasing significantly
the probability of a pregnancy, with an odds ratio (OR) of
1.628 and 1.083, respectively [17].
In another paper, a comparative analysis of legal restric-
tions on access to IVF was conducted in 13 EU countries.
This study demonstrated as countries with the most gen-
erous public financing scheme tended to restrict access to
IVF to a greater degree. Contrarily, no link was established
between IVF utilization and the manner in which coverage
was regulated or the level of public financing was set [18].
As a result of that, regulations seem generally more
restrictive compared to the eligibility criteria in order
to limit, through the reduced size of the covered popula-
tion the budgetary outlays [18].
Nowadays the cost of pharmacological therapies repre-
sent a major issue [19] at international level and it is often
considered as important as the effectiveness. Based on these
premises, in the present study we aimed at performing
a pharmaco economic analysis to estimate the cost-ef-
fectiveness of COS with r-FSH + r-LH in comparison
with HP-hMG, considering the effectiveness of r-FSH +
r-LH or HP-hMG (number of pregnancy, Positive or nega-
tive hCG test, Clinical pregnancy, Miscarriage, Cycle with
embryo freezing, and Dropout) in terms of the Quality
Adjusted Life Years (QALYs).
Methods
Model
A probabilistic decision tree was developed to simulate
the therapeutic path of two homogeneous cohorts of
1000 patients undergoing IVF, either using r-FSH + r-LH
or HP-hMG and to obtain COS. Also, the pharmaco-
logical treatment was analyzed (Fig. 1). The study was per-
formed in 2017.
The outcomes considered in the analysis were: (a)
urinary hCG pregnancy test (performed 15 days after
embryo transfer), (b) clinical pregnancy (foetal heartbeat
at transvaginal ultrasound performed 2–4 weeks after an
hCG+ test), (c) miscarriage (absence of foetal heartbeat
at transvaginal ultrasound in a patient with hCG+), and
(d) dropout from IVF program. The time horizon consid-
ered in the simulation was assumed to be equal to two
years, with a simulation of one IVF cycle every 6 months
for a maximum of 3 cycles. It was coherent with the litera-
ture [18] that underline how the most developed coun-
tries established public financing coverage limits for
three or four cycles [18]. In Italy, most couples are
submitted to a maximum of three IVF attempts during
a two-year period, after which they can continue to
undergo IVF, but without any reimbursement by the
healthcare system.
In detail, once the COS with r-FSH + r-LH or HP-hMG
had started, the patient was considered to have a different
probability of incurring in a positive or negative hCG test
according to the results previously published by
Revelli et al. [17]. In case of a positive pregnancy test,
the patient could have an US-detectable clinical preg-
nancy, in turn becoming an ongoing pregnancy or a mis-
carriage within the third month of pregnancy. In case of a
negative test, the patient could undergo an additional IVF
cycle using or not frozen embryos or decide to abandon
the therapeutic program (dropout). The model assumes
that patients without frozen embryos repeated the same
COS used in the previous fresh cycle.
The population considered in the model was the one
previously described by Revelli et al. [17], but we carried
out sub-analyses grouping patients in a different way, and
the following groups were created: 5–9 retrieved oocytes,
10–15 retrieved oocytes, and > 15 retrieved oocytes.
In order to estimate the QALYs of the two patient popu-
lations undertaking the therapeutic path with r-FSH +
r-LH or HP-hMG, the utilities reported in Table 1 were
considered. Due to the lack of precise information on the
impact of various events on the quality of life of patients
undergoing COS and IVF, the annual utility measures
used in the model were obtained through the opinion of
IVF experts.
The utilities reported in Table 1 and obtained through
the support of expert clinicians were transformed into
monthly utilities to perform the analysis.
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Each monthly utility was applied and weighed according
to the reference period reported in Table 1. The two
COS protocols were considered to have a priori identical
impact on the quality of life.
Transition probabilities
The probability of obtaining a positive hCG test and,
later on, having or not a miscarriage was obtained
through specific analyses carried out on the population
of 848 women enrolled in the real-life, previously pub-
lished in a clinical study [17]. Such probabilities were
calculated stratifying the population of patients accord-
ing to the type of COS therapy and to the number of re-
trieved oocytes (Table 2). The statistical significance was
evaluated with a chi-square test and Fisher’s exact test
when appropriate.
Analysing the general characteristics of the patients, it
was observed that by increasing the patients’ age, the
number of retrieved oocytes would decrease. In particular,
the average age of the patients (36.7 years for the whole
sample) was 36.4 for women with less than 5 retrieved oo-
cytes, 36.6 for women with 5–9 retrieved oocytes, 36 for
women with 10–15 retrieved oocytes, and 35.6 for women
with more than 15 retrieved oocytes. Therefore, the
model assumed that the probability of obtaining a posi-
tive hCG pregnancy test was likely to decrease with age
with an odds ratio of 0.901 (95% CI: 0.863–0.940) [17].
The transition probabilities of obtaining embryo freezing
as well as the probability of dropping-out from the IVF
program were assumed to be independent from the
number of retrieved oocytes, independent from the medi-
cation used for COS, and were estimated through the
expertise of clinical practice.
Cost parameters
The costs considered in the model refer only to the direct
costs covered by the Italian NHS for IVF treatment
Fig. 1 Cost Utility model structure – Decision tree
Table 1 Utilities considered in the model
Therapeutic path Utility Months Source
r-FSH + r-LH (MIN - MAX) 0.8 (0.72–0.88) 1 Expert opinion
HP-hMG (MIN - MAX) 0.8 (0.72–0.88) 1 Expert opinion
Positive hCGtest (MIN - MAX) 0.9 (0.81–0.99) 3 Expert opinion
Negative hCGtest (MIN - MAX) 0.7 (0.63–0.77) 5 Expert opinion
Clinical pregnancy (MIN - MAX) 1 (0.90–1.00) 2 Expert opinion
Miscarriage (MIN - MAX) 0.5 (0.45–0.55) 2 Expert opinion
Cycle with embryo freezing
(MIN - MAX)
0.9 (0.81–0.99) 1 Expert opinion
Cycle without embryo freezing
(MIN - MAX)
0.8 (0.72–0.88) 1 Expert opinion
Dropout (MIN - MAX) 0.4 (0.36–0.44) 6 Expert opinion
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(Table 3). For the cost estimates related to pregnancy
and miscarriage, we referred to the range of fees of hos-
pital health care for acute patients [20]. Specifically, as-
suming that 60% of patients would have a vaginal
delivery and the remaining 40% a caesarean section
(expert opinion based on the general trend in Italy
for IVF patients), such cost was obtained through a
weighted average of the Italian diagnosis-related
group (DRG) 371 (cesarean section without complica-
tions) and 373 (vaginal delivery without complica-
tions) rates. As far as miscarriage is concerned, the
cost was obtained as a simple average between DRG
376 (spontaneous miscarriage without surgery) and
377 (spontaneous miscarriage with dilatation and
curettage) rates.
The COS therapy medication cost was estimated on
the ex-factory price, that is the price set at the level of
the manufacturer, net of the discounts provided by law,
the formulation and the total dose observed in the refer-
ence study [17]. The cost of the monitoring before and
during COS was derived from the work of Papaleo et al.
[14] integrated by indications supplied by expert
opinions (Table 3).
Cost-effectiveness analysis
Cost-effectiveness analysis as applied to health econom-
ics provides an approach to medical decision making
[21]. A cost-effectiveness analysis is a type of economic
evaluation in which cost is expressed over some unit of
benefit (life years gained, symptom free months, etc.)
[21]. A cost-utility analysis is a type of cost-effectiveness
analysis in which the benefit is expressed in utility [21].
The most commonly used measure of benefit in a
cost-utility analysis is the QALY [21].
Quality-adjusted life years (QALYs) has become in-
creasingly used as a healthcare outcome measure and as
an integral part of cost-utility analysis [22, 23]. It com-
bines length of life and quality of life into a single index
number [24]. It is calculated as the area under the curve
when measuring utility over time [22]. The utility can be
Table 2 Transition probabilities used in the model
r-FSH + r-LH HP-hMG p-value for comparison Source
≥ 5 Oocytes
Positive hCG test (MIN - MAX) 0.34 (0.31–0.37) 0.23 (0.21–0.25) 0.007 Analyses from [17]
Negative hCG test (MIN - MAX) 0.66 (0.60–0.73) 0.77 (0.69–0.84)
Clinical pregnancy (MIN - MAX) 0.84 (0.76–0.92) 0.82 (0.74–0.90) 0.790
Miscarriage (MIN - MAX) 0.16 (0.15–0.18) 0,18 (0.16–0.19)
5–9 oocytes
Positive hCG test (MIN - MAX) 0.28 (0.26–0.31) 0.22 (0.20–0.24) 0.158 Analyses from [17]
Negative hCG test (MIN - MAX) 0.72 (0.65–0.79) 0.78 (0.70–0.86)
Clinical pregnancy (MIN - MAX) 0.82 (0.74–0.90) 0.79 (0.71–0.86) 0.646
Miscarriage (MIN - MAX) 0.18 (0.16–0.19) 0.21 (0.19–0.24)
10–15 oocytes
Positive hCG test (MIN - MAX) 0.43 (0.39–0.48) 0.24 (0.22–0.27) 0.025 Analyses from [17]
Negative hCG test (MIN - MAX) 0.57 (0.51–0.62) 0.76 (0.68–0.83)
Clinical pregnancy (MIN - MAX) 0.88 (0.80–0.97) 0.87 (0.78–0.95) 1.000
Miscarriage (MIN - MAX) 0.12 (0.10–0.13) 0.13 (0.12–0.15)
> 15 oocytes
Positive hCG test (MIN - MAX) 0.56 (0.50–0.61) 0.33 (0.30–0.37) 0.202 Analyses from [17]
Negative hCG test (MIN - MAX) 0.44 (0.40–0.49) 0.67 (0.60–0.73)
Clinical pregnancy (MIN - MAX) 0.80 (0.72–0.88) 1.00 (0.90–1.00) 0.524
Miscarriage (MIN - MAX) 0.20 (0.18–0.22) 0.00 (0.00–0.00)
Transition probabilities valid for all the sample
Cycle with embryo freezing (MIN - MAX) 0.30 (0.27–0.33) 0.30 (0.27–0.33) Expert opinion
Cycle without embryo freezing (MIN - MAX) 0.40 (0.36–0.44) 0.40 (0.36–0.44) Expert opinion
Dropout (MIN - MAX) 0.30 (0.27–0.33) 0.30 (0.27–0.33) Expert opinion
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thought of as the preference for a particular health state:
the greater the preference, the greater the utility associ-
ated with it [22]. Health state utilities are used to quan-
tify health-related quality of life and are ranked on a
scale 0–1, with 0 being equivalent to death and 1 being
a state of perfect health. Health state utilities measured
over time can be used to generate QALYs by multiplying
the duration in a particular health state by the utility as-
sociated with that state.
Most health conditions lie somewhere in between, al-
though it is possible for the lower bound to have a negative
value [25]. The effectiveness of r-FSH+ r-LH vs HP-hMG
was expressed has incremental QALY gained. Results were
expressed as an incremental cost-effectiveness ratio (ICER).
Mathematically, it can be described as ICER = (C1−C2)/
(E1 − E2), where C1 and E1 are the cost and effect in the
intervention or treatment group and where C2 and E2 are
the cost and effect in the control care group [21].
Sensitivity analysis
In order to consider the variability of the results based
on the model parameters, two sensitivity analyses were
conducted.
The first one (deterministic analysis) used a one-way
deterministic approach in which the model results were
obtained changing one parameter of the model at a time,
based on the variability found in the literature or as-
sumed by the authors. In this specific case, the following
scenarios were considered:
(a) probability to undergo an IVF cycle without embryo
freezing (base case = 0.4): Min = 0, Max = 1;
(b) probability to dropout from the therapeutic
program (base case = 0.3): Min = 0, Max = 1;
(c) change of transition probabilities based on the
assumed variability of ±5% compared to the base
case (Table 2);
(d) change of utilities associated with different health
conditions of a given patient based on an assumed
variability of ±5% compared to the base case
(Table 1);
(e) change of pregnancy and miscarriage costs
(pregnancy base case = € 1600.00, miscarriage
base case = € 1525.50): Min pregnancy (DRG 373) =
€ 1272.00, Max pregnancy (DRG 371) = € 2092.00;
Min miscarriage (DRG 376) = € 1264.00, Max
miscarriage (DRG 377) = € 1787.00;
(f ) probability to undergo an IVF cycle with embryo
freezing (base case = 0.3): Min = 0, Max = 1.
(g) follow-up (base case = 2 years): 1, 2 and 3 IVF cycles.
Table 3 Input data to calculate costs
Medications Dose (IU) Formulation (IU) Ex-factory price Source
r-FSH + r-LH 2453.46 150 € 72.55 [27]
HP-hMG 2801.49 75 € 16.10 [27]
Pre-treatment tests Frequency Unit cost Source
Hysterosalpingography 1 € 116.10 [14], expert opinion
Transvaginal ultrasound 1 € 45.90 [14], expert opinion
Gynaecological consultation 1 € 21.30 [14], expert opinion
Serum oestradiol (E2) 1 € 14.30 [14], expert opinion
Follicle-stimulating Hormone (FSH) 1 € 11.90 [14], expert opinion
Fertility test of the seminal fluid 1 € 7.90 [14], expert opinion
Luteinising Hormone (LH) 1 € 12.90 [14], expert opinion
Prolactin (PLR) 1 € 12.70 [14], expert opinion
Thyroid-stimulating Hormone (TSH) 1 € 12.40 [14], expert opinion
Free thyroxine (FT4) 1 € 12.60 [14], expert opinion
Free triiodothyronine (FT3) 1 € 12.70 [14], expert opinion
Blood samples drawing 1 € 2.70 [14], expert opinion
Tests during each IVF cycle Frequency Unit cost Source
Transvaginal ultrasound 3 € 45.90 [14], expert opinion
Gynaecological consultation 3 € 21.30 [14], expert opinion
Serum oestradiol (E2) 3 € 14.30 [14], expert opinion
Blood samples 3 € 2.70 [14], expert opinion
IU International Unit
Mennini et al. Reproductive Biology and Endocrinology  (2018) 16:68 Page 5 of 11
The second analysis (probabilistic analysis) was
conducted using a probabilistic sensitivity approach [Prob-
abilistic Sensitivity Analysis (PSA)], modeling all the pa-
rameters through Montecarlo simulations, each of them
according to a specific probabilistic distribution. The
probabilistic distribution was chosen applying what is gen-
erally reported for the development of the probabilistic
models in the economic evaluations, distinguishing be-
tween costs (gamma distribution) and epidemiological pa-
rameters (beta distribution) [19].
The results of the deterministic analysis were presented
through a tornado chart, while the results of the probabilis-




Based on the model simulations, the patients undergoing a
therapeutic protocol with r-FSH+ r-LH had a lower time to
pregnancy (TTP) than the women receiving HP-hMG (7.2
vs. 7.5 months for positive hCG test and 13.2 vs. 13.5 months
for clinical pregnancy, respectively) (Table 4). Furthermore,
the general success rate over the time horizon established in
the analysis (2 years) was higher for patients treated with
r-FSH+ r-LH, compared to HP-hMG, both in terms of posi-
tive hCG test (28.2% vs. 20.6%, respectively) and of clinical
pregnancy (23.6% vs. 17.0%, respectively) (Table 4).
These data were also confirmed after the stratifica-
tion of the results according to the number of retrieved
oocytes when patients with at least 5 oocytes were
considered (Fig. 2).
Cost-effectiveness results
Table 5 reports the results in terms of quality of life
(QALYs) and costs for each ongoing pregnancy (clinical
pregnancy without miscarriage) in the NHS perspective.
In particular, the cost of the drug and miscarriage/
pregnancy resulted to be higher in the r-FSH + r-LH
scenario (+€ 801,570 and + € 239,601 respectively),
whereas the monitoring cost was lower (−€ 67,552).
This was due to two main factors: (a) the number of
pregnancies using the r-FSH+ r-LH approach was higher
than with HP-hMG, with a higher absolute cost, but a
lower cost per pregnancy (€ 7375 vs € 7400 respectively)
and (b) the higher number of pregnancies and hCG positive
tests involved a higher cost for the NHS with an improve-
ment of the quality of life of over 4 QALYs gained for 100
women (Table 6).
With reference to the cost-effectiveness, Table 6 re-
ports the average cost-utility values per patient obtained
for the whole time horizon considered in the analysis,
stratified according to the number of retrieved oocytes.
The results indicate that, at the end of the analyzed
period, the ICER per QALY values were below a willing-
ness to pay of € 20,000 – 40,000.
Sensitivity analysis results
Figure 3 reports the results of the one-way deterministic
sensitivity analysis, for patients with ≥5 retrieved oo-
cytes. The parameters mostly influencing results are rep-
resented by the variation of the transition probabilities
concerning the possibility for the patient to undergo an
IVF cycle without embryo freezing and to quit the thera-
peutic program. In all the considered scenarios, the
ICER values never exceeded € 20,000 per QALY gained,
showing a good robustness of the results.
The probabilistic sensitivity analysis conducted accord-
ing to the number of retrieved oocytes, corresponding to
the population of patients with 10–15 retrieved oocytes,
confirmed that at the end of the observation period the
r-FSH + r-LH therapeutic protocol was cost-effective
compared with HP-hMG. Considering a willingness to
pay of about € 15,000, the probability that the r-FSH +
r-LH therapeutic protocol could result to be advanta-
geous with respect to HP-hMG resulted to be higher
than 80% (Fig. 4).
The results of the probabilistic analysis reported in Fig. 5
confirm the above calculation, showing higher uncertainty
in the short term (blue line). As the time horizon - and
consequently the number of IVF cycles - extends, the
cost-effectiveness probability increases. At the end of the
observation period, with a willingness to pay of about
Table 4 Epidemiological parameters from 1000 patients’
simulation – patients having at least 5 retrieved oocytes
HP-hMG r-FSH + r-LH
Cycle 1 clinical pregnancies 191 284
Cycle 2 clinical pregnancies 97 128
Cycle 3 clinical pregnancies 51 60
Clinical pregnancies 339 473
Average time at clinical pregnancy (months) 13.5 13.2
Clinical pregnancy rate 17.0% 23.6%
HP-hMG r-FSH + r-LH
Cycle 1 positive hCGtest 232 339
Cycle 2 positive hCG test 118 153
Cycle 3 positive hCG test 62 72
Positive hCG tests 413 563
Average time at positive hCG test (months) 7.5 7.2
Positive hCG test rate 20.6% 28.2%
HP-hMG r-FSH + r-LH
Miscarriages 37 45
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€ 35,000, the r-FSH + r-LH therapeutic protocol appeared
to be the most cost-effective with a probability higher
than 70%.
Discussion
The association of recombinant FSH plus recombinant
LH in 2:1 ratio (Pergoveris, Merck, Germany) may be
used not only to induce ovulation in anovulatory women
with hypogonadotropic hypogonadism [14], but also to
achieve multiple follicular developments in human IVF.
To date, there are still scarce or poorly informative data
that compared the COS using r-FSH + r-LH with that
obtained using other medications (e.g.HP-hMG) in the
IVF setting. Indeed in several studies [8–13] the urinary-
derived HP-hMG was compared to r-FSH alone, without
taking into account that HP-hMG contains not only
FSH, but also LH and hCG that act on the same recep-
tor of LH and have a powerful LH activity.
A randomized controlled trial (RCT) comparing
HP-hMG and r-FSH + r-LH in patients undergoing IVF
included only 122 women and showed comparable out-
comes in terms of pregnancy rate [16]. Unfortunately,
this study was clearly underpowered as it was designed
to assess the difference in oocyte rather than in the preg-
nancy rates. Another RCT study on 579 patients, in-
cluded patients submitted to intrauterine insemination
(IUI) rather than to IVF [15]. This showed comparable
outcomes, but without enough observations to show a
significant difference of effectiveness between medication.
In fact, IUI allows to get a much lower pregnancy
rate than the expected when using IVF in patients of
the same age (17.3% in the cited study [15] vs. ap-
proximately 30–40%).
To the best of our knowledge, the wider study compar-
ing HP-hMG and r-FSH + r-LH in IVF patients is a retro-
spective analysis of real-life data that included 848 women
classified as expected “poor” or “normal” responders to
gonadotropins [17]. Data were collected under real-life
practice circumstances in IVF Unit in S. Anna Hospital
(Torino, Italy), and the pregnancy rate with fresh embryo
transfer was calculated by stratifying patients according to
the number of retrieved oocytes, in order to exclude that a
difference in the results could be due to oocyte availability
[17]. The study showed an improvement in pregnancy rate
according to the increasing number of retrieved oocytes.
However, when comparing patients within the same oo-
cyte, the two medications obtained comparable results
when up to 4 oocytes, and a slight/ not significant advan-
tage with 5–8 oocytes. However, the PR/ET became sig-
nificantly higher when 9 or more oocytes were available
[17]. The multivariable logistic regression analysis con-
firmed that both the use of r-FSH + r-LH and the total
number of retrieved oocytes increased the probability
of pregnancy, with an odds ratio (OR) of 1.628 and
1.083, respectively, showing that the medication used
for COS was even more influent than the number of
oocytes itself.
Despite the contribution yielded by the previous lit-
erature in the field, the cost of COS, is still a major
issue in times of global economic restrictions. This is
relevant both in health systems where the patients
cover the costs with their own resources and in coun-
tries where the National Health Service (NHS) takes
care, partially or completely, of the expenses. Due to
the evidenced gap of knowledge and the relevance of
the proposed subject, the present study represents the
Fig. 2 Epidemiological parameters from simulations on patients stratified according to the number of retrieved oocytes
Table 5 Average cost and effectiveness results per 1000 patients – 2 years base case follow-up (patients with ≥5 retrieved oocytes)
Medication cost Monitoring cost Miscarriage/pregnancy cost Overall cost Pregnancies Cost per pregnancy
HP-hMG € 889,012 € 967,508 € 654,635 € 2,511,155 339 € 7400
r-FSH + r-LH € 1,690,582 € 899,956 € 894,236 € 3,484,774 473 € 7375
Difference +€ 801,570 -€ 67,552 +€ 239,601 +€ 973,618 + 133 -€ 25
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first attempt to evaluate the cost-effectiveness of COS
when recombinant gonadotropins in 2:1 combination
(Pergoveris) or HP-hMG are used in a large series of
patients undergoing IVF. Precisely we aimed to meas-
ure, through a sophisticated economic analysis the
overall cost-effectiveness of IVF cycles based on the
previously published database [17].
As a result, the present analysis demonstrates that
r-FSH + r-LH therapy showed higher cost-effectiveness
than HP-hMG in the considered two-years observation
periods with a slightly lower overall cost per pregnancy
despite a higher cost per medication. The cost-effectiveness
acceptability curve (CEAC) showed that the observed dif-
ference between the two medications was likely to further
increase if the time horizon was prolonged and the number
of IVF cycles rose. The advantage given by recombinant
gonadotropins vs. HP-hMG was not linked to a higher
number of retrieved oocytes because calculations were
Table 6 Cost-effectiveness table per number of retrieved oocytes (average results per treated patient)
Cost QALYs Incremental Cost Incremental QALYs ICER per QALYs
≥ 5 oocytes
HP-hMG € 1256 0.71
r-FSH + r-LH € 1742 0.76 € 487 0.04 € 11,365
5≤ oocytes≤ 9
HP-hMG € 1254 0.70
r-FSH + r-LH € 1726 0.73 € 472 0.03 € 16,309
10 ≤ oocytes≤ 15
HP-hMG € 1254 0.72
r-FSH + r-LH € 1751 0.80 € 497 0.08 € 6569
≥ 16 oocytes
HP-hMG € 1272 0.78
r-FSH + r-LH € 1824 0.82 € 551 0.04 € 12,274
Fig. 3 Deterministic sensitivity analysis – Tornado chart. ICER Incremental Cost-Effectiveness Ratio
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performed after patients’ stratification in subgroups and
having the same number of available oocytes. In detail,
for the population of patients obtaining 5 or more oo-
cytes, the r-FSH + r-LH therapy resulted to be highly
cost-effective compared with HP-hMG, with an ICER
period equal to €11,365 per QALY. Interestingly the pa-
tients that obtained the highest advantage from being
treated with r-FSH + r-LH instead of HP-hMG were
those with 10–15 retrieved oocytes, who had an ICER
of € 6569 per QALY. According to the medical
Fig. 4 Cost-effectiveness Acceptability Curve per number of retrieved oocytes. CE Cost Effectiveness
Fig. 5 Cost-effectiveness Acceptability Curve – ≥ 5 retrieved oocytes. CE Cost effectiveness
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literature, patients getting 10–15 retrieved oocytes are
among those with the best prognosis after fresh embryo
transfer [26] and may be considered “normal re-
sponders” to gonadotropin stimulation, representing
approximately 40–50% of the overall population under-
going IVF.
Our analysis, showed two main limitations: (a) the lack
of reports on the quality of life of patients undergoing
IVF did not allow an exact quantification of the utility
measures used in the model, some of which were obtained
considering the opinion of IVF experts; (b) the database
on which our analysis was based did not report about
embryo freezing and dropouts from the program. Even
in this case, their incidence was estimated according to
the opinion of IVF experts. However, the one-way sen-
sitivity analyses allow to take this uncertainty into ac-
count, and therefore these two limits should not have
affected the validity of our results. A final limitation, c)
regards the generalisability of our results on other
countries. This study was specifically settled on the Ital-
ian general practice and the model was populated with
Italian costs and tariffs different than what happens in
other European countries. However, the regulation in
Europe demonstrates a difference in term of access to
IVF [18]. Contrarily, no link was established between
IVF utilization and the manner in which coverage was
regulated or the level of public financing was set [18]. As a
result of that, we can assume that the general manage-
ment of these patients could be homogeneous around
Europe and the model structure represents a general ap-
proach for other countries. Further analysis, could con-
sider the same model structure adapting the specific
economic parameters and evaluate the cost-effectiveness
results for each country perspective. The National Health-
care Assistance in Italy covers the complete cost for go-
nadotropin treatment in IVF, provided that the patient is
younger than 45 and her basal FSH circulating level is
below 30 U/l. Not all countries have such a system, but
in general, most healthcare systems help patients to
face a percentage (variable in different countries) of
the economic cost of IVF medications and proced-
ure. Although the results found herein are not per-
fectly applicable to other countries due to such
differences in the healthcare assistance reimburse-
ment, the relative proportion of the cost of ovarian
stimulation with recombinant FSH and LH vs. hMG
is rather constant everywhere, and therefore the gen-
eral concepts expressed in this study may be of
interest even outside Italy.
The strength point of this analysis is that is based on
real-world data [17]; the transition probabilities used to
perform the model have been obtained from an Italian
study which collected data from clinical charts of IVF
Unit in S. Anna Hospital (Torino, Italy).
Conclusions
In conclusion, the present cost-utility analysis demon-
strated that the r-FSH + r-LH combination, although
more expensive than HP-hMG when medication costs
are considered, may be effectively used to obtain COS
in IVF patients without increasing the overall costs
for the patients or the NHS. On the contrary, the
r-FSH + r-LH association allows getting slightly reduced
costs for pregnancy, improved cost-effectiveness and
quality of life, especially when the so-called “normal-re-
sponders”, who represent the majority of IVF patients,
are considered.
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